Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
waveLINE-010: zilovertamab vedotin + R-CHP versus R-CHOP in previously untreated DLBCL
jRCT2061240099Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Merck & Co. Primary endpoint: progression-free survival. Started Mar 2025; status: recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2061240099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240099.